REPRISE
2017
Tolvaptan Safety and Efficacy in Later-Stage ADPKD
In 1,370 patients with later-stage ADPKD, tolvaptan slowed eGFR decline compared with placebo.
Result
Primary endpoint: Change in eGFR from baseline
−2.34 vs −3.61 mL/min/1.73m²/yr; difference 1.27 (95% CI 0.86–1.68; p<0.001).
- Subtopic
- ADPKD
- Design
- Double-blind RCT over 12 months
- Relevance
- Supporting: context rather than must-know.
- Cited in
- KDIGO 2025 ADPKD
- Source
- Torres VE, et al. N Engl J Med. 2017;377(20):1930-1942.doi 10.1056/NEJMoa1710030
Discussion & critique
Extended the tolvaptan indication to more advanced CKD stages of ADPKD.